Scribe Therapeutics (NASDAQ:SCTX) Issues Quarterly Earnings Results, Beats Expectations By $2.36 EPS

Key Points

• Scribe Therapeutics reported quarterly EPS of negative $3.84, beating the consensus estimate of negative $6.20 by $2.36.
• Shares rose to $30.90 in midday trading, while analysts maintained a bullish outlook; the stock has a consensus “Buy” rating and an average price target of $51.75.
• Insiders purchased approximately 3.73 million shares worth $56.3 million over the past 90 days, though the clinical-stage biotechnology company continues to forecast substantial losses in coming periods.

Scribe Therapeutics (NASDAQ:SCTX - Get Free Report) posted its earnings results on Wednesday. The company reported ($3.84) EPS for the quarter, beating the consensus estimate of ($6.20) by $2.36, Zacks reports.

Scribe Therapeutics Price Performance

Shares of SCTX traded up $1.90 during midday trading on Wednesday, reaching $30.90. The stock had a trading volume of 278,607 shares, compared to its average volume of 232,297. Scribe Therapeutics has a 52 week low of $17.31 and a 52 week high of $39.60.

Insider Transactions at Scribe Therapeutics

In other Scribe Therapeutics news, Director Behzad Aghazadeh purchased 2,383,333 shares of the business's stock in a transaction on Friday, July 24th. The stock was bought at an average cost of $15.15 per share, with a total value of $36,107,494.95. Following the acquisition, the director owned 3,080,983 shares of the company's stock, valued at $46,676,892.45. The trade was a 341.62% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Bio Fund Ii L.P. Ah acquired 333,333 shares of Scribe Therapeutics stock in a transaction dated Monday, July 27th. The shares were acquired at an average price of $15.00 per share, with a total value of $4,999,995.00. Following the transaction, the insider owned 2,385,075 shares in the company, valued at approximately $35,776,125. This represents a 16.25% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders acquired 3,727,237 shares of company stock worth $56,291,746.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Wall Street Zen raised Scribe Therapeutics to a "hold" rating in a research note on Saturday, August 1st. Leerink Partners began coverage on shares of Scribe Therapeutics in a report on Tuesday, August 18th. They issued an "outperform" rating and a $37.00 price objective for the company. HC Wainwright assumed coverage on shares of Scribe Therapeutics in a research report on Monday. They issued a "buy" rating and a $60.00 target price for the company. Guggenheim initiated coverage on shares of Scribe Therapeutics in a research note on Tuesday, August 18th. They set a "buy" rating and a $50.00 target price on the stock. Finally, Wells Fargo & Company initiated coverage on shares of Scribe Therapeutics in a research report on Tuesday, August 18th. They set an "overweight" rating and a $60.00 price target on the stock. Four research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Scribe Therapeutics has a consensus rating of "Buy" and an average target price of $51.75.

Scribe Therapeutics News Summary

Here are the key news stories impacting Scribe Therapeutics this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $60 price target, implying considerable upside from recent trading levels. The firm’s coverage provides a new bullish valuation reference for the clinical-stage biotechnology company. HC Wainwright Begins Coverage on Scribe Therapeutics
• Positive Sentiment: HC Wainwright expects Scribe’s quarterly losses to narrow after the second quarter of 2026, forecasting EPS of negative $1.02 in Q3 2026 and negative $1.05 in Q4 2026, compared with negative $6.20 in Q2 2026. The firm projects a negative $4.90 EPS loss for fiscal 2027, better than its negative $6.72 forecast for fiscal 2026.
• Neutral Sentiment: Management will participate in upcoming investor conferences, including the Wells Fargo Healthcare Conference. These events could provide updates on Scribe’s in vivo CRISPR pipeline, but no new clinical, regulatory, or financial data was announced. Scribe Therapeutics to Participate in Upcoming Investor Conferences
• Negative Sentiment: Despite the bullish rating, HC Wainwright still forecasts sizable losses across every listed period, including negative $1.10 to negative $1.36 EPS in the first four quarters of 2027. Continued losses and the absence of reported clinical or partnership developments remain risks for SCTX investors.

About Scribe Therapeutics

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source